

Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 18th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynecologists, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

Educational material

The event educational material can be downloaded starting November 20th on www.askit.accmed.org

Programme

Thurso	lay,	Novem	ber	3 rd
--------	------	-------	-----	-----------------

Inurs	day, November 3 rd
10.00	Introduction to the Conference Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat
	SESSION I - EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION Chairpersons: Hesham Ahmed Gaballah Elghazaly, Aleix Prat
10.30	Biological heterogeneity and clinical outcomes in HR+/HER2- negative disease Maria Vittoria Dieci
11.00	PDL1, TMB, TROP2, immune infiltration and genomic classifiers in TNBC Giampaolo Bianchini
11.30	Is HER2-low breast cancer a real entity? Scoring issues and biological heterogeneity Giuseppe Viale
12.00	HER2+ early breast cancer: potential role of genomic classifiers Aleix Prat
12.30	Q&A
13.00	Lunch
	SESSION II - CHANGING PARADIGMS FOR LOCOREGIONAL TREATMENTS. MASTECTOMY, BREAST RECONSTRUCTION AND RADIATION THERAPY Chairpersons: Jaceck Jassem, Philip Poortmans
14.00	When is breast-conserving therapy really not avoidable Oreste Gentilini
14.30	Breast reconstruction: when and how? Vincenzo Vindigni

Radiation therapy after breast reconstruction

15.00

Orit Kaidar-Person

15.30 Q	&A
----------------	----

	Multidisciplinary Tumor Board 1 – Locoregional treatment Panelists: Bettina Borisch, Oreste Gentilini, Jacek Jassem, Eleftherios Mamounas, Orit Kaidar-Person, Philip Poortmans, Fedro Peccatori
16.00	Clinical case 1. Second breast conserving therapy – Tania Saibene
16.15	Clinical case 2. Patient with lymph node seen on planning CT-scan: what now? (RT) – Silvia Michieletto
16.30	Clinical case 3. BOOP: after or due to radiation therapy – Luca Visani
16.45	Concluding comments: Eleftherios Mamounas, Fedro Peccatori
17.00	Adjourn
17.45	Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2022
18.00	Lecture of the Awardee

19.30 Adjourn

Cocktail

The Ceremony and the cocktail will take place in Palazzo Bo, Via VIII Febbraio 2, Padua

Friday, November 4th

SESSION III – EARLY BREAST CANCER. FINE TUNING FROM DE-ESCALATION TO ESCALATION

Chairpersons: Pierfranco Conte, Miguel Martin

- 9.00 Tailoring neoadjuvant/adjuvant treatment for triple negative breast cancer Sibylle Loibl
- 9.30 Risk adapted treatment of early HR+/HER2- breast cancer: from modulation of endocrine treatment to novel agents
 Stephen Johnston
- 10.00 Is there a role for anthracyclines in contemporary treatment of early breast cancer? Valentina Guarneri
- 10.30 **Q&A**

11.00	Coffee Break
	Multidisciplinary Tumor Board 2 - Early breast cancer Panelists: Bettina Borisch, Pierfranco Conte, Valentina Guarneri, Jacek Jassem, Stephen Johnston, Sibylle Loibl, Miguel Martin, Fedro Peccatori
11.30	Clinical case 1. Node positive, premenopausal patient: role of genomic classifiers – Cristina Falci
11.45	Clinical case 2. HR+HER2+ patient with residual disease after neoadjuvant therapy – Federica Miglietta
12.00	Clinical case 3. Adjuvant treatment in rare histologies – Grazia Vernaci
12.15	Concluding comments: Jaceck Jassem, Miguel Martin
12.30	Lunch
	SESSION IV – METASTATIC BREAST CANCER: NEW OPTIONS, NEW ALGORITHMS Chairpersons: Bettina Borisch, Alessandra Gennari
13.30	HER2+ advanced breast cancer: new treatment algorithms Sandra Swain
14.00	TN advanced breast cancer: biology-driven treatment algorithms Hope Rugo
14.30	HR+ advanced breast cancer: what after CDK4/6? Giuseppe Curigliano
15.00	Q&A
	Multidisciplinary Tumor Board 3 – Metastatic Breast Cancer Panelists: Bettina Borisch, Pierfranco Conte, Giuseppe Curigliano, Hesham Ahmed Gaballah Elghazaly, Hope Rugo, Sandra Swain
15.30	Clinical case 1. Brain metastases – Gaia Griguolo
15.45	Clinical case 2. Possibility of discontinuing treatment in very long term responders – Carlo Alberto Giorgi
16.00	Clinical case 3. Locoregional treatment for oligometastatic disease or role of NGS in ABC – Michele Bottosso

Concluding comments: Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly

Take home messages and adjourn

16.15

16.30

Honorary President

Gabriel N. Hortobagyi

Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer Center
Houston (USA)

Directors

Pierfranco Conte

Coordinator Molecular Tumor Board, Rete Oncologica Veneta, Padova (I) Scientific Director S. Camillo Hospital, IRCCS, Venezia (I)

Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Philip Poortmans

Former president of ESTRO and of ECCO Department of Radiation Oncology Iridium Netwerk University of Antwerp Wilrijk-Antwerp (B)

Aleix Prat

Medical Oncology Department Hospital Clinic Barcellona (E)

Scientific Committee

Bettina Borisch

Institute of Global Health University of Geneva (CH)

Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Hesham Ahmed Gaballah Elghazaly

Department of Clinical Oncology and nuclear medicine University of Ainshams Cairo (EG)

Jacek Jassem

Department of Oncology and Radiotherapy Medical University of Gdansk (PL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

Sibylle Loibl

German Breast Group University of Frankfurt (D)

Eleuterios Mamounas

Comprehensive Breast Program MD Anderson Cancer Center Orlando Orlando (USA)

Miguel Martin

Medical Oncology Service Hospital Universitario Gregorio Marañon Madrid (E)

Fedro Alessandro Peccatori

Department of Medical Oncology European Institute of Oncology (IEO) Milano (I)

Sandra Swain M.

Research Development Georgetown University Medical Center Washington (USA)

Speakers

Giampaolo Bianchini

Breast Unit IRCC S. Raffaele Hospital Milano (I)

Michele Bottosso

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Giuseppe Curigliano

Department of Oncology European Institute of Oncology University of Milan (I)

Maria Vittoria Dieci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Cristina Falci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Alessandra Gennari

Division of Oncology Ospedale Maggiore della Carità UPO – University of Piemonte Orientale Novara

Valentina Guarneri

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padova (I)

Oreste Davide Gentilini

Breast Unit IRCC S. Raffaele Hospital Milano (I)

Carlo Alberto Giorgi

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Gaia Griguolo

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Orit Kaidar-Person

Breast Cancer Radiation Therapy Unit Sheba Medical Center Ramat Gan (IL)

Stephen Johnston

NIHR Biomedical Research Centre for Cancer Royal Marsden NHS Foundation Trust & Institute of Cancer Research London (UK)

Sibylle Loibl

German Breast Group University of Frankfurt (D)

Silvia Michieletto

Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Federica Miglietta

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Aleix Prat

Medical Oncology Department Hospital Clinic Barcellona (E)

Hope Rugo

Breast Oncology Clinical Trials Program UCSF Carol Franc Buck Breast Care Center San Francisco (USA)

Tania Saibene

Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Sandra Swain M.

Research Development Georgetown University Medical Center Washington (USA)

Grazia Vernaci

Division of Medical Oncology 2 Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Giuseppe Viale

Department of Pathology European Institute of Oncology University of Milan (I)

Vincenzo Vindigni

Breast Surgery Istituto Oncologico Veneto IRCCS Department of Surgery, Oncology and Gastroenterology University of Padua (I)

Luca Visani

U.O. di Radioterapia AOU Careggi Firenze

CME

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-355554): 8,4 CME credits.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialization and highly specialized activity. Rare disease.

The credit certification for the webinar is subject to:

- Professions/specializations should correspond to those which have been accredited for CME;
- attendance at the 90% of the meeting;
- the completion of the Meeting evaluation online form;
- completion of the final test (at least 75% of correct answers). 1 attempt admitted.

The test and the meeting evaluation form must be completed within 3 days from the end of the event.

Award & Fellowships

UNIVERSITY OF PADUA AWARD FOR ADVANCES IN BREAST CANCER 2022

The Scientific Committee will select young researchers (< 40 years from any country) who have published in an international peer-reviewed journal, as the principal author, a manuscript reporting important clinical or biological advances in breast cancer. The Scientific Committee will select the final winner which will be invited to present his/her study during the annual Conference.

FELLOWSHIPS

Some fellowship (for under 40) will be awarded including registration and 2 Hotel nights. Those interested should send a short CV and a motivation letter within October 10th to *info.bologna@accmed.org*

The organizing secretariat will confirm the award of the fellowship within October 20th and proceed with the organization of logistics.

UNDER 40

Accademia will provide a limited amount of free registrations for Physicians, Biologists, Pharmacists and Nurses "Under 40". Those interested should send email within October 10th to *info.bologna@accmed.org*. The organizing secretariat will confirm the registration by email.



Registration

Onsite participation registration fees

- € 250,00 for Physicians
- € 150,00 for Graduate students and Nurses

The onsite fee includes: » Participation to the meeting in Padova

» Access to the educational material » Refreshments during the breaks (coffee, lunch)

Digital event registration fees

- € 180,00 for Physicians
- € 100,00 for graduate students and Nurses

The digital fee includes: » Participation at the digital congress

» Access to the educational material

All fees are in €.

When registering, it is necessary to select the desired option until exhaustion of the available places. Please register at https://fad.accmed.org/course/info.php?id=900 before October 25th, 2022. Only online registration will be accepted. No registration will be accepted on site.

CANCELLATION AND REFOUNDS

• In case of cancellation, please give notice to the Organizing Secretariat (info.bologna@accmed.org) within 10 days before the beginning of the Meeting. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be refounded

How to participate the meeting

Participants who will follow the Digital Event will need a good quality internet connection and a device (PC, smartphone, tablet) with a recent internet browser (e.g. any updated version of Chrome or Firefox).

For those attending in Padova, AccMed recommends to:

- Wear a FFP2 face mask covering nose and mouth
- Do not enter the meeting venue with a body temperature higher than 37,5°
- Wash or sanitise your hands often
- Reduce close contact

Further details on security measures are available at: https://fad.accmed.org/sicurezza

Meeting Venue

Auditorium
San Gaetano Altinate Cultural Center

Via Altinate, 71 Padova

How to reach the venue:

The Center is located in the ZTL area.

We recommend the parking in Piazza Insurrezione in the historic center of Padua (the area is accessible and there are no electronic gates).

Supported by unrestricted educational grants from

GOLD SPONSOR



SILVER SPONSOR







BRONZE SPONSOR







CONTRIBUTORS









With the patronage of

INSTITUTIONS













SCIENTIFIC SOCIETIES













